Peptides
PT-141
Bremelanotide
Category
Melanocortin peptide
Half-life
~2.5 hours
Typical dose
1–2 mg
Frequency
As needed (45–60 min before)
Route
Subcutaneous injection
Mechanism
PT-141 (bremelanotide) is a melanocortin receptor agonist acting centrally on MC3R and MC4R receptors in the hypothalamus. Unlike PDE5 inhibitors (Viagra, Cialis) which act peripherally on blood flow, PT-141 works centrally on the nervous system to increase sexual desire and arousal. FDA approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Research summary
PT-141 is FDA approved (Vyleesi) — the only approved centrally-acting sexual dysfunction treatment. Clinical trials demonstrated improved desire and reduced distress in women with HSDD. Off-label research in males shows similar effects. Nausea is the most common side effect at higher doses.
Storage
Lyophilized: −20°C. Reconstituted: 2–8°C up to 4 weeks.
Key studies
Kingsberg SA, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. Obstetrics & Gynecology. DOI: 10.1097/AOG.0000000000003500
Frequently asked questions
How does PT-141 work differently from Viagra?
Viagra acts peripherally — it increases blood flow to genital tissue. PT-141 acts centrally in the brain, activating melanocortin receptors in the hypothalamus to increase sexual desire. It works regardless of blood flow and addresses the desire component rather than the physical response.
What are PT-141 side effects?
Nausea is the most common side effect, particularly at doses above 1.75mg. Flushing and transient blood pressure elevation also occur. Starting at lower doses (0.5–1mg) reduces nausea risk significantly.
For research use only. Not intended for human consumption. Not medical advice. Consult a licensed physician before use.